Trade

Cohance Lifesciences share price

Balanced risk
  • 37%Low risk
  • 37%Moderate risk
  • 37%Balanced risk
  • 37%High risk
  • 37%Extreme risk
  • 691.25(-0.01%)
    November 12, 2025 15:10:30 PM IST
    • NSE
    • BSE
  • Vol : 268.41K (NSE + BSE)
    Last 20 day avg : 791.65 K

Cohance Lifesciences is trading -0.01% lower at Rs 691.25 as compared to its last closing price. Cohance Lifesciences has been trading in the price range of 698.95 & 687.50. Cohance Lifesciences has given -38.09% in this year & -6.43% in the last 5 days. Cohance Lifesciences has TTM P/E ratio 102.73 as compared to the sector P/E of 29.66.There are 8 analysts who have initiated coverage on Cohance Lifesciences. There are 4 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 48.88 Crores in its last quarter.Listed peers of Cohance Lifesciences include Biocon (5.06%), Laurus Labs (0.35%), Suven Pharmaceuticals (-0.01%).The Mutual Fund holding in Cohance Lifesciences was at 16.49% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Cohance Lifesciences was at 6.51% in 30 Sep 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Key Metrics

Updated on Nov 12, 2025, 09:44 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.66
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.16
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    10.58
    In line with historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    75.38
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
687.50
Highest
698.95
52 week range
Lowest
688.20
Highest
1,359.00
Cohance Lifesciences Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in June quarter by 12.55% from Rs 549.31 crore to Rs 488.08 crore, year-on-year
    • financial-insightsThe company's profit declined by 35.15% year-on-year during the June quarter, dropping from Rs 75.37 crore to Rs 48.88 crore
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Cohance Lifesciences Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 773.70
  • R2
  • 804.35
  • R3
  • 847.10
Pivot730.95
  • S1
  • 700.30
  • S2
  • 657.55
  • S3
  • 626.90
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Cohance Lifesciences Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Biocon
Bullish
404.605.0654,093.5547.702.080.1359.81
Laurus Labs
Bullish
989.350.3553,440.10129.299.150.1615.82
Suven Pharmaceuticals
Bearish
691.25-0.0126,454.5296.4015.12-10.36
Ipca Laboratories
Neutral
1,340.001.3434,048.2740.795.170.288.55
Ajanta Pharma
Moderately Bullish
2,573.10-0.1732,115.4135.778.672.050.92
Cohance Lifesciences Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Cohance Lifesciences is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holds a high stake in the company at 57.49%
    • InsightsPromoter(s) have increased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 0.72 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 7.59 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    DSP Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 260.83
    • % of AUM 8.81
    ITI Pharma and Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 10.70
    • % of AUM 4.84
    Mirae Asset Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 104.34
    • % of AUM 3.88
    Invesco India Focused Fund Regular Growth
    5/5
    • Amount Invested (Cr.) 107.43
    • % of AUM 2.70
    UTI Healthcare Fund Regular Plan Growth
    NA
    • Amount Invested (Cr.) 28.14
    • % of AUM 2.65
    Cohance Lifesciences Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-11-12Quarterly Results
    2025-05-28Audited Results
    2025-02-12Quarterly Results
    2024-11-12Quarterly Results
    2024-08-09Quarterly Results
    About the company Cohance Lifesciences
    • IndustryBiotechnology & Drugs
    • ISININE03QK01018
    • BSE Code543064
    • NSE CodeCOHANCE
    Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
    • Management Info
    • Vivek SharmaAdditional Executive Chairman of the Board
    • Sudhir SinghChief Executive Officer
    • Himanshu AgarwalChief Financial Officer
    • Gaurav BahadurChief Human Resources Officer
    • Kundan JhaCompliance Officer and Company Secretary
    • Vetukuri Venkata Prasada RajuManaging Director, Executive Director
    Cohance Lifesciences Share Price FAQs

    Cohance Lifesciences is trading at 691.25 as on Wed Nov 12 2025 09:40:30. This is -0.01% lower as compared to its previous closing price of 691.30.

    The market capitalization of Cohance Lifesciences is 26454.52 Cr as on Wed Nov 12 2025 09:40:30.

    The average broker rating on Cohance Lifesciences is Strong Buy. The breakup of analyst rating is given below -

    • 4 analysts have given a strong buy rating
    • 4 analysts have given a buy rating
    • 0.00 analysts have given a hold rating
    • 0.00 analysts have given a sell rating
    • 0.00 analysts have given a strong sell rating

    The 52 wk high for Cohance Lifesciences is 1359.00 whereas the 52 wk low is 688.20

    Cohance Lifesciences can be analyzed on the following key metrics -

    • TTM P/E: 102.73
    • Sector P/E: 29.66
    • Dividend Yield: 0.00%
    • D/E ratio: -

    Cohance Lifesciences reported a net profit of 267.87 Cr in 2025.

    The Mutual Fund Shareholding was 16.49% at the end of 30 Sep 2025.